Joseph P. McGuirk

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam et al. · New England Journal of Medicine · 2018 · 3.9K citations · Full text

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al. · New England Journal of Medicine · 2021 · 1.4K citations · Full text

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil, Michael D. Jain, Lei Feng et al. · Journal of Clinical Oncology · 2020 · 752 citations · Full text

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 528 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 492 citations · Full text

Lymphoid Neoplasia, Hematology, Immunology +6